港股異動丨華寶國際(0336.HK)三日累漲30% 電子煙第一股思摩爾國際即將上市
格隆匯7月2日丨華寶國際(0336.HK)大漲逾14%,報3.88港元,近三個交易日累計漲幅達30%,總市值120.6億港元。其附屬華寶股份(300741.SZ)亦大漲超8%。華寶作為香精香料行業的領導者,業務涵蓋煙用、食用和日用香精香料三大領域,銷售額在同行業一直名列前茅,特別是在煙用香精香料領域佔據絕對領導地位。而全球最大電子霧化設備製造商思摩爾國際預計於7月10日在港交所掛牌上市。儘管隨着電子煙消費者羣體的不斷擴大,思摩爾業績持續高增長,2019年,思摩爾收入同比增長121.6%至76.11億元,純利同比增長196.2%至21.74億元。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.